XTNT

SEC source: 0001235802-20-000118 · primary_doc.xml · nonDerivative · entry 1

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Foonotes

Disclosed balance after: 52,702,384

F1 · kind: See Exhibit 99.1

F1 · price: See Exhibit 99.1

F2 · ownership.nature: These securities are held of record by ROS Acquisition. OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.

F3 · ownership.nature: Each of ROS Acquisition, ORO II, Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.

SEC source: 0001235802-20-000119 · primary_doc.xml · nonDerivative · entry 2

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 15,300,688

F1 · kind: See Exhibit 99.1

F1 · price: See Exhibit 99.1

F3 · ownership.nature: Each of ROS Acquisition, ORO II, Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.

F4 · ownership.nature: These securities are held of record by ORO II. OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II.

SEC source: 0001235802-20-000119 · primary_doc.xml · nonDerivative · entry 1

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 52,702,384

F1 · kind: See Exhibit 99.1

F1 · price: See Exhibit 99.1

F2 · ownership.nature: These securities are held of record by ROS Acquisition. OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.

F3 · ownership.nature: Each of ROS Acquisition, ORO II, Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.

SEC source: 0001235802-20-000097 · primary_doc.xml · derivative · entry 2

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,942

Underlying: Common Stock · 119,942 shares

Expires 2030-08-15

F3 · derivative.exercise_date: This option vests with respect to 29,986 shares on August 15, 2021 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments., subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc.

SEC source: 0001235802-20-000097 · primary_doc.xml · nonDerivative · entry 1

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,352

F1 · shares: These shares will vest and be issued with respect to 23,796 shares on each of August 15, 2021, August 15, 2022 and August 15, 2023 and with respect to 23,795 shares on August 15, 2024 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.

F2 · balance_after: Includes 161,560 shares that will be issued over time subject to vesting pursuant to restricted stock units granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.

SEC source: 0001235802-20-000098 · primary_doc.xml · derivative · entry 2

JENSEN GREG · CIK 0001199647 · VP, Finance and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,942

Underlying: Common Stock · 119,942 shares

Expires 2030-08-15

F3 · derivative.exercise_date: This option vests with respect to 29,986 shares on August 15, 2021 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments., subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc.

SEC source: 0001235802-20-000098 · primary_doc.xml · nonDerivative · entry 1

JENSEN GREG · CIK 0001199647 · VP, Finance and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,081

F1 · shares: These shares will vest and be issued with respect to 23,796 shares on each of August 15, 2021, August 15, 2022 and August 15, 2023 and with respect to 23,795 shares on August 15, 2024 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.

F2 · balance_after: Includes 120,607 shares that will be issued over time subject to vesting pursuant to restricted stock units granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.

SEC source: 0001235802-20-000048 · primary_doc.xml · derivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 868,016

Underlying: Common Stock · 868,016 shares

Expires 2030-05-06

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain First Amendment to Second Amended and Restated Credit Agreement, effective as of April 1, 2020.

F2 · balance_after: Only represents derivative securities of this class.

F4 · ownership.nature: This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC ("ROF II"). Each of ROS Acquisition and OrbiMed Royalty Opportunities II, LP ("ORO II") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

F5 · ownership.nature: These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II.

SEC source: 0001235802-20-000048 · primary_doc.xml · derivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,531,984

Underlying: Common Stock · 1,531,984 shares

Expires 2030-05-06

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain First Amendment to Second Amended and Restated Credit Agreement, effective as of April 1, 2020.

F2 · balance_after: Only represents derivative securities of this class.

F3 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.

F4 · ownership.nature: This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC ("ROF II"). Each of ROS Acquisition and OrbiMed Royalty Opportunities II, LP ("ORO II") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001235802-20-000047 · primary_doc.xml · derivative · entry 2

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 868,016

Underlying: Common Stock · 868,016 shares

Expires 2030-05-06

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain First Amendment to Second Amended and Restated Credit Agreement, effective as of April 1, 2020.

F2 · balance_after: Only represents derivative securities of this class.

F4 · ownership.nature: Each of ROS Acquisition, OrbiMed Royalty Opportunities II, LP ("ORO II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.

F5 · ownership.nature: These securities are held of record by ORO II. OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II.

SEC source: 0001235802-20-000047 · primary_doc.xml · derivative · entry 1

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,531,984

Underlying: Common Stock · 1,531,984 shares

Expires 2030-05-06

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain First Amendment to Second Amended and Restated Credit Agreement, effective as of April 1, 2020.

F2 · balance_after: Only represents derivative securities of this class.

F3 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.

F4 · ownership.nature: Each of ROS Acquisition, OrbiMed Royalty Opportunities II, LP ("ORO II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.

SEC source: 0001235802-20-000046 · primary_doc.xml · derivative · entry 2

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 868,016

Underlying: Common Stock · 868,016 shares

Expires 2030-05-06

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain First Amendment to Second Amended and Restated Credit Agreement, effective as of April 1, 2020.

F2 · balance_after: Only represents derivative securities of this class.

F4 · ownership.nature: Each of ROS Acquisition, OrbiMed Royalty Opportunities II, LP ("ORO II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.

F5 · ownership.nature: These securities are held of record by ORO II. OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II.

SEC source: 0001235802-20-000046 · primary_doc.xml · derivative · entry 1

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,531,984

Underlying: Common Stock · 1,531,984 shares

Expires 2030-05-06

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain First Amendment to Second Amended and Restated Credit Agreement, effective as of April 1, 2020.

F2 · balance_after: Only represents derivative securities of this class.

F3 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.

F4 · ownership.nature: Each of ROS Acquisition, OrbiMed Royalty Opportunities II, LP ("ORO II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.

SEC source: 0001235802-20-000008 · primary_doc.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 91,256

F4 · kind: See Exhibit 99.2.

F2 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 35,211 shares on February 15, 2021 and with respect to 35,212 shares on February 15, 2022, conditioned upon Michael Eggenberg and Matthew Rizzo, respectively, remaining directors of Xtant through the vesting date.

F3 · ownership.nature: This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

F4 · ownership.nature: See Exhibit 99.2.

SEC source: 0001235802-20-000008 · primary_doc.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 91,256

F1 · kind: See Exhibit 99.1.

F2 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 35,211 shares on February 15, 2021 and with respect to 35,212 shares on February 15, 2022, conditioned upon Michael Eggenberg and Matthew Rizzo, respectively, remaining directors of Xtant through the vesting date.

F1 · ownership.nature: See Exhibit 99.1.

F3 · ownership.nature: This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001235802-20-000006 · primary_doc.xml · nonDerivative · entry 1

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,256

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 35,211 shares on February 15, 2021 and with respect to 35,212 shares on February 15, 2022, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes (i) 70,423 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date; and (ii) 20,833 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F3 · ownership.direct: See Exhibit 99.1

F4 · ownership.direct: Each of ROS Acquisition, ORO II, Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001235802-20-000007 · primary_doc.xml · nonDerivative · entry 1

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,256

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 35,211 shares on February 15, 2021 and with respect to 35,212 shares on February 15, 2022, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes (i) 70,423 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date; and (ii) 20,833 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F3 · ownership.direct: See Exhibit 99.1.

F4 · ownership.direct: Each of ROS Acquisition, ORO II, Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001235802-20-000004 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,057

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 58,098 shares on February 15, 2021 and with respect to 58,099 shares on February 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes (i) 116,197 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date; (ii) 9,027 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and (iii) 10,417 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested.

SEC source: 0001235802-20-000005 · primary_doc.xml · nonDerivative · entry 1

Peters Jeffrey J · CIK 0001329814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,794

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 58,098 shares on February 15, 2021 and with respect to 58,099 shares on February 15, 2022, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes (i) 116,197 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date; (ii) 5,555 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and (iii) 13,021 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested.

SEC source: 0001235802-20-000003 · primary_doc.xml · nonDerivative · entry 1

BAKEWELL JOHN K · CIK 0001183553 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,794

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 58,098 shares on February 15, 2021 and with respect to 58,099 shares on February 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes (i) 116,197 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date; (ii) 5,555 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and (iii) 13,021 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested.

SEC source: 0001790300-19-000006 · primary_doc.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 20,833

F4 · kind: See Exhibit 99.2.

F2 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon Michael Eggenberg and Matthew Rizzo, respectively, remaining directors of Xtant through the vesting date.

F3 · ownership.nature: This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

F4 · ownership.nature: See Exhibit 99.2.

SEC source: 0001790300-19-000006 · primary_doc.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 20,833

F1 · kind: See Exhibit 99.1.

F2 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon Michael Eggenberg and Matthew Rizzo, respectively, remaining directors of Xtant through the vesting date.

F1 · ownership.nature: See Exhibit 99.1.

F3 · ownership.nature: This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001790300-19-000007 · primary_doc.xml · nonDerivative · entry 1

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,833

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · ownership.direct: The Reporting Person is an employee of OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended. Upon vesting of the restricted stock unit award, ownership of the shares underlying the restricted stock unit award will be transferred to ROS Acquisition Offshore LP ("ROS Acquisition") and OrbiMed Royalty Opportunities II, LP ("ORO II"). Advisors is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a.r.l., of which ROS Acquisition is a wholly-owned subsidiary. OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition and ORO II and, as a result, may be deemed to have beneficial ownership over such securities.

F3 · ownership.direct: Each of ROS Acquisition, ORO II, Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001790300-19-000005 · primary_doc.xml · nonDerivative · entry 1

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,833

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · ownership.direct: The Reporting Person is an employee of OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended. Upon vesting of the restricted stock unit award, ownership of the shares underlying the restricted stock unit award will be transferred to ROS Acquisition Offshore LP ("ROS Acquisition") and OrbiMed Royalty Opportunities II, LP ("ORO II"). Advisors is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a.r.l., of which ROS Acquisition is a wholly-owned subsidiary. OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition and ORO II and, as a result, may be deemed to have beneficial ownership over such securities.

F3 · ownership.direct: Each of ROS Acquisition, ORO II, Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001235802-19-000129 · primary_doc.xml · derivative · entry 2

Browne Sean E · CIK 0001790461 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 329,044

Underlying: Common Stock · 329,044 shares

Expires 2029-10-15

F2 · derivative.exercise_date: This option vests with respect to 65,809 shares on each of October 15, 2020, October 15, 2021, October 15, 2022 and October 15, 2023 and with respect to 65,808 shares on October 15, 2024 pursuant to an option award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining an employee of Xtant through the vesting date.

SEC source: 0001235802-19-000129 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 329,044

F1 · shares: These shares will vest and be issued with respect to 65,809 shares on each of October 15, 2020, October 15, 2021, October 15, 2022 and October 15, 2023 and with respect to 65,808 shares on October 15, 2024 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining an employee of Xtant through the vesting date.

F1 · balance_after: These shares will vest and be issued with respect to 65,809 shares on each of October 15, 2020, October 15, 2021, October 15, 2022 and October 15, 2023 and with respect to 65,808 shares on October 15, 2024 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining an employee of Xtant through the vesting date.

SEC source: 0001235802-19-000122 · primary_doc.xml · nonDerivative · entry 1

BAKEWELL JOHN K · CIK 0001183553 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,597

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 5,555 shares to be issued upon vesting pursuant to restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and 13,021 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested.

SEC source: 0001235802-19-000123 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,860

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 9,027 shares to be issued upon vesting pursuant to restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and 10,417 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested.

SEC source: 0001235802-19-000121 · primary_doc.xml · nonDerivative · entry 1

Peters Jeffrey J · CIK 0001329814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,597

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 5,555 shares to be issued upon vesting pursuant to restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and 13,021 shares issued as part of a restricted stock award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, which shares are subject to forfeiture until vested.

SEC source: 0001235802-19-000104 · primary_doc.xml · derivative · entry 2

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,527

Underlying: Common Stock · 40,527 shares

Expires 2029-08-15

F3 · derivative.exercise_date: This option vests with respect to 10,131 shares on August 15, 2020 and with respect to 10,132 shares on each of August 15, 2021, August 15, 2022 and August 15, 2023, subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc.

SEC source: 0001235802-19-000104 · primary_doc.xml · nonDerivative · entry 1

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,169

F1 · shares: These shares will vest and be issued with respect to 8,792 shares on each of August 15, 2020, August 15, 2021 and August 15, 2022 and with respect to 8,793 shares on August 15, 2023 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.

F2 · balance_after: These shares will be issued over time subject to vesting pursuant to restricted stock units granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.

SEC source: 0001235802-19-000103 · primary_doc.xml · derivative · entry 2

JENSEN GREG · CIK 0001199647 · VP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,063

Underlying: Common Stock · 39,063 shares

Expires 2029-08-15

F2 · derivative.exercise_date: This option vests with respect to 9,765 shares on August 15, 2020 and with respect to 9,766 shares on each of August 15, 2021, August 15, 2022 and August 15, 2023, subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc.

SEC source: 0001235802-19-000103 · primary_doc.xml · nonDerivative · entry 1

JENSEN GREG · CIK 0001199647 · VP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,898

F1 · shares: These shares will vest and be issued with respect to 8,474 shares on each of August 15, 2020 and August 15, 2021 and with respect to 8,475 shares on each of August 15, 2022 and August 15, 2023 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.

F1 · balance_after: These shares will vest and be issued with respect to 8,474 shares on each of August 15, 2020 and August 15, 2021 and with respect to 8,475 shares on each of August 15, 2022 and August 15, 2023 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.

SEC source: 0000947871-19-000265 · ownership.xml · derivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 434,008

Underlying: Common Stock · 434,008 shares

Expires 2029-04-01

F4 · kind: This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Second Amended and Restated Credit Agreement, effective as of March 29, 2019.

F2 · ownership.nature: These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, ROF II and Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II.

F3 · ownership.nature: This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition, ORO II and the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The reporting persons have designated two representatives, currently Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or the reporting person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-19-000265 · ownership.xml · derivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 765,992

Underlying: Common Stock · 765,992 shares

Expires 2029-04-01

F4 · kind: This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Second Amended and Restated Credit Agreement, effective as of March 29, 2019.

F1 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.

F3 · ownership.nature: This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition, ORO II and the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The reporting persons have designated two representatives, currently Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or the reporting person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0001235802-19-000037 · primary_doc.xml · derivative · entry 2

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 434,008

Underlying: Common Stock · 434,008 shares

Expires 2029-04-01

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain Second Amended and Restated Credit Agreement, dated as of March 29, 2019.

F2 · balance_after: Only represents derivative securities of this class.

F4 · ownership.nature: Each of ROS Acquisition, OrbiMed Royalty Opportunities II, LP ("ORO II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

F5 · ownership.nature: These securities are held of record by ORO II. OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.

SEC source: 0001235802-19-000037 · primary_doc.xml · derivative · entry 1

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 765,992

Underlying: Common Stock · 765,992 shares

Expires 2029-04-01

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain Second Amended and Restated Credit Agreement, dated as of March 29, 2019.

F2 · balance_after: Only represents derivative securities of this class.

F3 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.

F4 · ownership.nature: Each of ROS Acquisition, OrbiMed Royalty Opportunities II, LP ("ORO II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0001235802-19-000036 · primary_doc.xml · derivative · entry 2

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 434,008

Underlying: Common Stock · 434,008 shares

Expires 2029-04-01

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain Second Amended and Restated Credit Agreement, dated as of March 29, 2019.

F2 · balance_after: Only represents derivative securities of this class.

F4 · ownership.nature: Each of ROS Acquisition, OrbiMed Royalty Opportunities II, LP ("ORO II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

F5 · ownership.nature: These securities are held of record by ORO II. OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.

SEC source: 0001235802-19-000036 · primary_doc.xml · derivative · entry 1

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 765,992

Underlying: Common Stock · 765,992 shares

Expires 2029-04-01

F1 · price: This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain Second Amended and Restated Credit Agreement, dated as of March 29, 2019.

F2 · balance_after: Only represents derivative securities of this class.

F3 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.

F4 · ownership.nature: Each of ROS Acquisition, OrbiMed Royalty Opportunities II, LP ("ORO II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0001235802-19-000008 · primary_doc.xml · derivative · entry 2

Berlin Ronald G. · CIK 0001764230 · VP & Chief Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common stock · 100,000 shares

Expires 2029-01-15

F1 · derivative.exercise_date: This option vests with respect to 25,000 shares on each of January 15, 2020, January 15, 2021, January 15, 2022 and January 15, 2023, subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc.

SEC source: 0001235802-18-000155 · primary_doc.xml · derivative · entry 2

Mainelli Michael · CIK 0001315983 · Director · Interim CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2028-10-15

F2 · derivative.exercise_date: This option vests with respect to 10,000 of the shares subject to the option on the 15th day of each of the twenty-four (24) months commencing on November 15, 2018, subject to such Reporting Person's continued employment as Chief Executive Officer of Xtant Medical Holdings, Inc.

SEC source: 0000947871-18-000752 · ownership.xml · derivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 434,008

Underlying: Common Stock · 434,008 shares

Expires 2028-08-01

F4 · kind: This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Twenty-Fifth Amendment to the Amended and Restated Credit Agreement, effective as of August 1, 2018.

F2 · ownership.nature: These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II.

F3 · ownership.nature: Each of ROS Acquisition, ORO II and the reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or the reporting person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-18-000752 · ownership.xml · derivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 765,992

Underlying: Common Stock · 765,992 shares

Expires 2028-08-01

F4 · kind: This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Twenty-Fifth Amendment to the Amended and Restated Credit Agreement, effective as of August 1, 2018.

F1 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.

F3 · ownership.nature: Each of ROS Acquisition, ORO II and the reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or the reporting person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0001235802-18-000147 · primary_doc.xml · derivative · entry 4

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 434,008

Underlying: Common Stock · 434,008 shares

Expires 2028-08-01

F4 · kind: This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Twenty-Fifth Amendment to the Amended and Restated Credit Agreement, effective as of August 1, 2018.

F2 · ownership.nature: These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Each of ROS Acquisition, ORO II, Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0001235802-18-000147 · primary_doc.xml · derivative · entry 3

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 765,992

Underlying: Common Stock · 765,992 shares

Expires 2028-08-01

F4 · kind: This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Twenty-Fifth Amendment to the Amended and Restated Credit Agreement, effective as of August 1, 2018.

F1 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.

F2 · ownership.nature: These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities.

SEC source: 0001235802-18-000146 · primary_doc.xml · derivative · entry 4

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 434,008

Underlying: Common Stock · 434,008 shares

Expires 2028-08-01

F4 · kind: This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Twenty-Fifth Amendment to the Amended and Restated Credit Agreement, effective as of August 1, 2018.

F2 · ownership.nature: These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Each of ROS Acquisition, ORO II, Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0001235802-18-000146 · primary_doc.xml · derivative · entry 3

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 765,992

Underlying: Common Stock · 765,992 shares

Expires 2028-08-01

F4 · kind: This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Twenty-Fifth Amendment to the Amended and Restated Credit Agreement, effective as of August 1, 2018.

F1 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.

F2 · ownership.nature: These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities.

SEC source: 0001235802-18-000144 · primary_doc.xml · derivative · entry 2

Lenzen Kathie J. · CIK 0001750873 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2028-09-15

F1 · derivative.exercise_date: This option vests with respect to 32,500 shares on each of September 15, 2019, September 15, 2020, September 15, 2021 and September 15, 2022, subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc.

SEC source: 0001235802-18-000122 · primary_doc.xml · derivative · entry 2

Brandt Kevin D · CIK 0001692661 · VP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,770

Underlying: Common Stock · 30,770 shares

Expires 2028-08-15

F2 · derivative.exercise_date: This option vests with respect to 7,692 shares on each of August 15, 2019 and August 15, 2020 and with respect to 7,693 shares on each of August 15, 2021 and August 15, 2022, subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc.

SEC source: 0001235802-18-000122 · primary_doc.xml · nonDerivative · entry 1

Brandt Kevin D · CIK 0001692661 · VP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · shares: These shares will vest and be issued on July 9, 2021 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.

F1 · balance_after: These shares will vest and be issued on July 9, 2021 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.